DCGI allowed emergency use of this drug of Zydus Cadila for the treatment of corona
All the efforts taken by the government are inadequate and the patients of Corona are continuously dying.
DCGI approved the emergency use of ‘Virafin’ for the use of corona patients.
Corona’s uncontrollable pace has created a serious crisis in the country. All the efforts taken by the government are inadequate and the patients of Corona are continuously dying. Meanwhile, the Drugs Controller General of India (DCGI) has approved the emergency use of ‘Virafin’ of Ahmedabad-based drug maker Zydus Cadila.
Zydus Cadila stated that Pegylated Interferon alpha-2b, ‘Virafin’ is greatly helped by emergency use in adults with Kovid-19 infection. Zydus Cadila said that ‘Virafin’ will be provided to hospitals.
Earlier, Zydus Cadila had sought approval from the Drug Controller General of India for the treatment of Kovid-19. The company had said that the drug Pegylated Interferon Alpha 2b or PegiHep has proved to be effective 91.15 percent. The initial third-phase human trial yielded promising results from the drug. Interim results indicated that timely delivery of the drug may help patients recover more quickly and avoid the complication seen in the advanced stages of the disease.
Pegylated Interferon Alpha 2b or PegiHep is an approved drug in India and has been re-formulated for the treatment of Kovid-19. Preliminary results of Phase III human testing showed that drug use cured 91.15 percent of covid-19 patients within 7 days and their positive corona test report was negative in the RT-PCR test.
The company claims that Pegylated Interferon Alpha 2b or PegiHep is a single dose drug. With single dose medicine, treatment will be less cumbersome and more economical for the patients. According to the company, during the test, drug dependent patients also had less need for oxygen support. This makes it clear that the drug is able to control shortness of breath, which is a major challenge in the treatment of covid-19.
“We are excited by the results of the Phase III trial of Pegylated Interferon Alpha 2b which confirmed the possibility of reducing the impact of the virus on timely use of the disease,” said Shravil Patel of Cadila Healthcare. In December 2020, the company was given permission from the drug regulator to start Phase III human trials on covid-19 patients.
